Bak MTJ, van Ruler O, Stassen L, Ruiterkamp M, Arkenbosch JHC, Dijkstra G, Campmans-Kuijpers MJE, van Meeteren NLU, Bongers BC, Romberg-Camps M, van der Marel S, Hoentjen F, van Dongen KW, West R, van der Woude J, de Vries AC; Dutch Initiative Crohn and Colitis (ICC) and Dutch Initiative on Crohn and Colitis – Surgery (ICC-S).Int J Colorectal Dis. 2023 Oct 19;38(1):254. doi: 10.1007/s00384-023-04537-z.PMID: 37855846 Free PMC article.
Publicaties uit 2023
Therapeutic drug monitoring of methotrexate in patients with Crohn’s disease
van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, Mares WGN, Mahmmod N, van Asseldonk DP, Lutgens MWMD, Kuyvenhoven JP, Rietdijk ST, Nissen LHC, Koehestanie P, de Boer NKH, de Jonge R, Bouma G, Bulatović Ćalasan M; Dutch Initiative on Crohn and Colitis (ICC).
Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719. Online ahead of print.
Prognostic value of the modified Rutgeerts’ score for long-term outcomes after primary ileocecal resection in Crohn’s disease
Bak MTJ, Huinink STB, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps MJ, de Boer NKH, Hoentjen F, Stassen LPS, van der Meulen-de Jong AE, West RL, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC); Dutch Initiative on Crohn and Colitis (ICC).
Am J Gastroenterol. 2023 Sep 22. doi: 10.14309/ajg.0000000000002509. Online ahead of print.
Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship
Wijnands AM, Elias SG, Dekker E, Fidder HH, Hoentjen F, Ten Hove JR, Maljaars PWJ, van der Meulen-de Jong AE, Mooiweer E, Ouwehand RJ, Penning de Vries BBL, Ponsioen CY, van Schaik FDM, Oldenburg B; Dutch Initiative on Crohn’s and Colitis (ICC).
United European Gastroenterol J. 2023 Sep;11(7):612-620. doi: 10.1002/ueg2.12426. Epub 2023 Jul 28. Free PMC article.
Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease
Kreijne JE, Goetgebuer RL, Erler NS, De Boer NK, Siebers AG, Dijkstra G, van Kemenade FA, Hoentjen F, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC).
Aliment Pharmacol Ther. 2023 Jul;58(2):207-217. doi: 10.1111/apt.17555. Epub 2023 May 23
[Inflammatory bowel disease]
Straatmijer T, Duijvestein M, van Dop W, Stassen L, Derikx M, Bureo, Gonzalez A, Mujagic Z, Pierik M, van Schaik F, Peters C, Derikx L, de Groof J, Bennebroek Evertsz F, van der Bilt J, Visschedijk M, West R, Romkens T, van der Meulen A
Ned Tijdschr Geneeskd. 2023 Aug 31;167:D7680. Dutch.
Endoscopic and surgical treatment outcomes of colitis-associated advanced colorectal neoplasia: a multicenter cohort study
Derks ME, Te Groen M, Peters CP, Dijkstra G, de Vries AC, Romkens TE, Horjus CS, de Boer NK, Bemelman WA, Nagtegaal ID, Derikx LA, Hoentjen F; Dutch Initiative on Crohn and Colitis.
Int J Surg. 2023 Jul 1;109(7):1961-1969. doi: 10.1097/JS9.0000000000000335. Free PMC article.
Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn’s disease patients in stable remission: the randomised controlled LADI trial
Jansen FM, van Linschoten RCA, Kievit W, Smits LJT, Pauwels RWM, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, Hoentjen F, van der Woude CJ; LADI study group and the Dutch Initiative on Crohn and Colitis (ICC).
J Crohns Colitis. 2023 Jun 13:jjad101. doi: 10.1093/ecco-jcc/jjad101. Online ahead of print.
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Straatmijer T, Biemans VBC, Moes DJAR, Hoentjen F, Ter Heine R, Maljaars PWJ, Theeuwen R, Pierik M, Duijvestein M, van der Meulen-de Jong AE; Dutch Initiative on Crohn’s and Colitis (ICC).
Dig Dis Sci. 2023 Jun;68(6):2647-2657. doi: 10.1007/s10620-023-07822-7. Epub 2023 Mar 15. Free PMC article.
Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group and the Dutch Initiative on Crohn and Colitis.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):343-355. doi: 10.1016/S2468-1253(22)00434-4. Epub 2023 Jan 31. Clinical Trial.
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease
Mahmoud R, Savelkoul EHJ, Mares W, Goetgebuer R, Witteman BJM, de Koning DB, van Tuyl SAC, Minderhoud I, Lutgens MWMD, Akol-Simsek D, van Schaik FDM, Fidder HH, Jansen JM, van Boeckel PGA, Mahmmod N, Horjus-Talabur Horje CS, Römkens TEH, Colombel JF, Hoentjen F, Jharap B, Oldenburg B; Dutch Initiative on Crohn’s and Colitis (ICC) and the AWARE study group.
Clin Gastroenterol Hepatol. 2023 Mar;21(3):750-760.e4. doi: 10.1016/j.cgh.2022.08.024. Epub 2022 Aug 31. Free article.
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
Straatmijer T, Biemans VBC, Visschedijk M, Hoentjen F, de Vries A, van Bodegraven AA, Bodelier A, de Boer NKH, Dijkstra G, Festen N, Horjus C, Jansen JM, Jharap B, Mares W, van Schaik FDM, Ponsioen C, Romkens T, Srivastava N, van der Voorn MMPJA, West R, van der Woude J, Wolvers MDJ, Pierik M, van der Meulen-de Jong AE, Duijvestein M; Initiative on Crohn and Colitis.
Clin Gastroenterol Hepatol. 2023 Jan;21(1):182-191.e2. doi: 10.1016/j.cgh.2022.04.038. Epub 2022 May 26. Free article.
Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodulator for recurrence of Crohn’s disease after ileocecal resection results in prolonged continuation as compared to anti-tumor necrosis factor monotherapy
Ten Bokkel Huinink S, Beelen EMJ, Ten Bokkel Huinink T, Hoentjen F, G L Bodelier A, Dijkstra G, Romberg-Camps M, de Boer NK, Stassen LPS, van der Meulen AE, West R, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC).
Eur J Gastroenterol Hepatol. 2023 Jan 1;35(1):45-51. doi: 10.1097/MEG.0000000000002474. Epub 2022 Nov 7.